Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

被引：0
|
作者：
Aleš Linhart
Gabriela Dostálová
Kathy Nicholls
Michael L. West
Camilla Tøndel
Ana Jovanovic
Pilar Giraldo
Bojan Vujkovac
Tarekegn Geberhiwot
Einat Brill-Almon
Sari Alon
Raul Chertkoff
Rossana Rocco
Derralynn Hughes
机构：
[1] Charles University and General University Hospital in Prague,2nd Department of Internal Cardiovascular Medicine, First Faculty of Medicine
[2] Royal Melbourne Hospital and The University of Melbourne,Department of Nephrology
[3] Dalhousie University,Division of Nephrology, Department of Medicine
[4] University of Bergen,Department of Clinical Science
[5] Haukeland University Hospital,Nephrology and Rheumatology Unit, Department of Pediatrics
[6] Salford Royal,Department of Inherited Metabolic Disease
[7] Hospital de Dia Quiron,Centro de Investigación Biomédica en Red de Enfermedades Raras
[8] General Hospital Slovenj Gradec,Department of Internal Medicine
[9] University Hospitals Birmingham NHS Foundation Trust and University of Birmingham,Department of Diabetes, Endocrinology and Metabolism
[10] Protalix Biotherapeutics,Lysosomal Storage Disorders Unit
[11] Chiesi Farmaceutici S.p.A.,undefined
[12] Royal Free London NHS Foundation Trust and University College London,undefined
来源：
Orphanet Journal of Rare Diseases | / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
    Linhart, Ales
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael L.
    Tondel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Geberhiwot, Tarekegn
    Brill-Almon, Einat
    Alon, Sari
    Chertkoff, Raul
    Rocco, Rossana
    Hughes, Derralynn
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [2] A SUBGROUP ANALYSIS OF FEMALE PATIENTS IN A PHASE 3 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PEGUNIGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE PREVIOUSLY TREATED WITH AGALSIDASE ALFA
    Hughes, Derralynn
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael
    Tandel, Camilla
    Jovanovic, Ana
    Castellano, Pilar Giraldo
    Vujkovac, Bojan
    Geberhiwot, Tarekegn
    Almon, Einat
    Alon, Sari
    Szlaifer, Mali
    Chertkoff, Raul
    Linhart, Ales
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [3] Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study
    Linhart, Ales
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael
    Tondel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Hiwot, Tarekegn
    Almon, Einat
    Alon, Sari
    Szlaifer, Mali
    Chertkoff, Raul
    Hughes, Derralynn
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S65 - S65
  • [4] Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study
    Bernat, John
    Holida, Myrl
    Longo, Nicola
    Goker-Alpan, Ozlem
    Wallace, Eric
    Deegan, Patrick
    Nedd, Khan
    Tondel, Camilla
    Eyskens, Francois
    Feldt-Rasmussen, Ulla
    Pisani, Antonio
    Rocco, Rossana
    Almon, Einat
    Alon, Sari
    Chertkoff, Raul
    Warnock, David
    Waldek, Stephen
    Wilcox, William
    GENETICS IN MEDICINE, 2022, 24 (03) : S91 - S92
  • [5] Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa
    Linhart, Ales
    Nicholls, Kathy
    West, Michael
    Tondel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Almon, Einat
    Alon, Sari
    Amit-Cohen, Bat-chen
    Szlaifer, Mali
    Chertkoff, Raul
    Hughes, Derralynn
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S94 - S94
  • [6] Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study
    Linhart, Ales
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael
    Tendel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Hiwot, Tarekegn
    Brill-Almon, Einat
    Alon, Sari
    Szlaifer, Mali
    Chertkoff, Raul
    Hughes, Derralynn
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S98 - S99
  • [7] An open-label, switchover trial to assess the safety and efficacy of agalsidase beta in patients with Fabry disease treated with agalsidase alfa enzyme replacement therapy
    Richards, Sarah
    Laney, Dawn
    Pervaiz, Muhammad A.
    Shankar, Suma
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S90 - S90
  • [8] Pharmacokinetic (PK) Results From a Phase 3 Trial to Evaluate Pegunigalsidase Alfa Every 4 Weeks (Q4W) in Patients (Pts) With Fabry Disease Previously Treated With Agalsidase Beta or Agalsidase Alfa
    Tondel, Camilla
    Wallace, Eric L.
    Rocco, Rossana
    Almon, Einat
    Alon, Sari
    Blinder-Haddad, Liora
    Chertkoff, Raul
    Warnock, David G.
    Waldek, Stephen
    Pisani, Antonio
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 389 - 390
  • [9] Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study
    Schiffmann, Raphael
    Pastores, Gregory
    Peter, Chang
    Rick, Martin
    Anna, Wijatyk
    MOLECULAR GENETICS AND METABOLISM, 2013, 108 (02) : S81 - S82
  • [10] Renal and secondary outcomes 1 year after switching from agalsidase alfa to pegunigalsidase alfa for Fabry disease (the BRIDGE study)
    Hughes, Deralynn
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael
    Tondel, Camilla
    Jovanovic, Ana
    Giraldo, Pilar
    Vujkovac, Bojan
    Hiwot, Tarekegn
    Almon, Einat
    Alon, Sari
    Szlaifer, Mali
    Chertkoff, Raul
    Linhart, Ales
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S107 - S108
12345